CD46 and Miyoshi myopathy: There may be a fitness advantage present in treatment-naïve primary MM cells associated with patient treatment history and how it relates to the bone marrow microenvironment of fetal tissue; thus, newly diagnosed samples were used to study CD46–ADC.